iSBTc 22nd Annual Meeting

Annual Meeting Main Page   |   Award Winners   |   Download Final Program
CME Information   |   Documents & News Releases   |   Presentation Slides & Schedule
Faculty   |   Pictures   |   Download Abstracts

November 2 - 4, 2007
Seaport World Trade Center
Boston, Massachusetts

Presentations
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the next to the speaker's name for the slides you wish to view.

Schedule at a Glance  |  Presentations  |  Friday Presentations  |  Saturday Presentations  |  Sunday Presentations

Friday, November 2
7:50 am - 8:00 am	President's Welcome Jon M. Wigginton, MD - Merck & Co., Inc.
8:00 am - 8:45 am	Richard V. Smalley Memorial Lectureship Interferons (IFNs) for Cancer: Defining Biological Response Modification and Full Therapeutic Potential Ernest C. Borden, MD - Cleveland Clinic Foundation
8:45 am - 11:30 am	Plenary Session: Cellular Therapies Co-Chairs: Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center James C. Yang, MD - National Cancer Institute
8:45 am - 9:15 am	Adoptive Cellular Therapy: Sustained Regression of Large Tumor Burdens with In Vitro Expanded T-Cells James C. Yang, MD - National Cancer Institute
9:15 am - 9:45 am	Targeting Tumors with Genetically Enhanced T Lymphocytes Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
9:45 am - 10:15 am	Engineering Cytolytic Effector Cells for Glioma Immunotherapy Using Gene Insertion and Zinc Finger Nuclease Genomic Editing Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute
10:45 am - 11:00 am	A Comprehensive Platform for T Cell Expansion Based on Biodegradable Artificial Antigen-Presenting Microparticulates Tarek Fahmy, PhD - Yale University
11:00 am - 11:15 am	Tumor-Specific CD4 T Cells are Required for Long-Term Anti-Tumor Immunity in Reconstituted Lymphopenic Animals Kevin Friedman, PhD - Earle A. Chiles Research Institute
11:15 am - 11:30 am	T-Cell Therapy for the Control of EBV-Related Nasopharyngeal Carcinoma Paulo Pedrazzoli, MD - Ospedale Niguarda Ca’ Granda
1:30 pm - 3:30 pm	Plenary Session: Characterizing the Host Response to Cancer Co-Chairs: George Coukos, MD, PhD - University of Pennsylvania Medical Center Thomas F. Gajewski, MD, PhD - University of Chicago
1:30 pm - 2:00 pm	Stat3 Mediates a Crosstalk Between Tumor Cells and Immune Cells in the Tumor Microenvironment Hua Yu, PhD - City of Hope National Medical Center
2:00 pm - 2:15 pm	Antibody Immunity to a Panel of Oncogenic Proteins May Predict Presence of Colon Cancer and Stage of Disease Vivian Goodell, MPH - University of Washington
2:15 pm - 2:30 pm	A Possible Role for Regulatory T-Cells in Survival Differences Between Helicobacter Pylori Posititve and Negative Gastric Cancer Patients After Curative Tumor Resection Hauke Winter, MD - Klinikum Grosshadern, Ludwig-Maximilians University of Munich
2:30 pm - 2:45 pm	Immunophenotypic Analysis of Melanoma Metastases: A New Approach for Prognostication in Stage IV Melanoma Alicia M. Terando, MD - John Wayne Cancer Institute
2:45 pm - 3:00 pm	A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on CD8+ T Effector/Memory Cells Via CD137 Rimas J. Orentas, PhD - Medical College of Wisconsin
3:00 pm - 3:30 pm	Endothelin (B) Receptor Mediates the Endothelial Barrier to T-Cell Homing to Tumors, and Its Neutralization Enables Tumor Immune Therapy George Coukos, MD, PhD - University of Pennsylvania Medical Center
3:45 pm - 5:15 pm	Concurrent Session I: Cytokines Co-Chairs: Michael T. Lotze, MD - University of Pittsburgh Crystal Mackall, MD - National Cancer Institute
3:45 pm - 4:15 pm	Interleukin 1 Family Members Regulate Tumor Immunity in Response to Damage Associated Molecular Pattern Molecules (DAMPs) Michael T. Lotze, MD - University of Pittsburgh Cancer Institute
4:15 pm - 4:30 pm	IL-24 and Its Role in Wound Healing Nancy J. Poindexter, PhD - MD Anderson Cancer Center
4:30 pm - 4:45 pm	Intra-Tumoral IL-12 Promotes CD8 + T-Effector/Memory Cell- Mediated IFN-Gamma and FASL-Dependent Elimination of CD4+ CD25+ FOX3+ T-Suppressor Cells from Tumors Mehmet O. Kilinc, PhD - University at Buffalo / SUNY
4:45 pm - 5:15 pm	Interleukin-7 Therapy in Humans: Proof-of-Principle Crystal Mackall, MD - National Cancer Institute, Pediatric Oncology
3:45 pm - 5:15 pm	Concurrent Session II: Angiogenesis and Vascular Therapies Co-Chairs: Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy Renata Pasqualini, PhD - MD Anderson Cancer Center
3:45 pm - 3:50 pm	Introduction Renata Pasqualini, PhD - MD Anderson Cancer Center
3:50 pm - 4:25 pm	Ligand-Directed Targeting and Molecular Genetic Imaging in Diseases with an Angiogenesis Component Wadih Arap, MD, PhD - MD Anderson Cancer Center
4:25 pm - 5:00 pm	Tie2-Expressing Monocytes: a Novel Lineage of Proangiogenic Cells Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
5:00 pm - 5:15 pm	Impaired Angiogenesis in Aminopeptidase N-Null Mice Roberto Rangel, PhD - MD Anderson Cancer Center
Saturday, November 3
8:00 am - 8:45 am	Saturday Keynote Address Adoptive T Cell Therapy: Grand Challenges and Opportunities Carl H. June, MD - University of Pennsylvania
8:45 am - 11:30 am	Plenary Session: Immuoregulation and Mediated Tolerance Co-Chairs: Vincenzo Bronte, MD - Istituto Oncologico Veneto F. Stephen Hodi, MD - Dana-Farber Cancer Institute
8:45 am - 9:00 am	Elevated Foxp3+CD4+CD25+ Regulatory T Cells in Tumor-Bearing Mice Suppress T-Cell Priming, Effector-Cell Function and Anti-Tumor Immunity Zuqiang Liu, PhD - University of Pittsburgh School of Medicine
9:00 am - 9:30 am	Manipulating Immune Tolerance Unmasks the Latent Immune-Modulating Potential of Cancer Therapeutics Leisha A. Emens, MD, PhD - Johns Hopkins University
9:30 am - 9:45 am	Different Flavors of Regulatory T-Cell (Treg) Subsets in Patients with Cancer and Their Role in Tumor Escape Christoph Bergmann, MD, PhD - University of Duisburg-Essen
9:45 am - 10:00 am	Ex Vivo Depletion of CD81+ Tumor-Induced Regulatory T Cells Restores Priming of Tumor-Specific Effector T Cells Generated in Reconstituted, Lymphopenic Hosts Christian Poehlein, MD - Earle A. Chiles Research Institute
10:00 am - 10:15 am	Foxp3 is Expressed by Tumor Cells, Virally Transformed B Cells, and Germ Cells Weisan Chen, PhD - Ludwig Institute for Cancer Research
10:45 am - 11:00 am	TGF-Beta Signaling Plays a Crucial Role for De Novo Induction of Adaptive Regulatory T Cells but Is Not Required for the Immunosuppressive Effect Mediated by Tumor-Induced Regulatory T Cells Ulf Petrausch, MD - Earle A. Chiles Research Institute
11:00 am - 11:30 am	Myeloid-Derived Suppressor Cells in Cancer Vincenzo Bronte, MD - Istituto Oncologico Veneto
1:30 pm - 3:00 pm	Concurrent Session I: Tumor Recognition / Immune Evasion Co-Chairs: Paul F. Robbins, PhD - National Cancer Institute Thomas Spies, PhD - Fred Hutchinson Cancer Research Center
1:30 pm - 2:00 pm	Adoptive Immunotherapy of Malignancies with Gene Modified, EBV-Specific, Cytotoxic T-Cell Lines Malcolm K. Brenner, MD, PhD - Baylor College of Medicine
2:00 pm - 2:30 pm	Therapeutically Accessible Molecules That Regulate the Regulators Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine
2:30 pm - 2:45 pm	Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Immune Reactivity to Neuroblastoma In Vivo Bryon D. Johnson, PhD - Medical College of Wisconsin
2:45 pm - 3:00 pm	5-aza-2’- Deoxycytidine Treatment Increases Expression of Tumor Associated Antigens in Human Melanoma Timothy Haggerty, PhD - CytoCure LLC
1:30 pm - 3:00 pm	Concurrent Session II: New Agents Co-Chairs: Elizabeth A. Repasky, PhD - Rosewell Park Cancer Institute Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
1:30 pm - 1:45 pm	PTTG-1: An Immunological Target for Multiple Myeloma Maurizio Chiriva, PhD - Texas Tech University Health Sciences Center
1:45 pm - 2:00 pm	A Phase II Study of Tremelimumab (CP-675,206), an Anti-CTLA4 Monoclonal Antibody, in Patients with Refractory Metastatic Colorectoal Cancer Ki Y. Chung, MD - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:15 pm	Immune-Related Adverse Events in Patients with Melanoma Treated with Tremelimumab (CP-675,206) Dimitri Pavlov, PhD - Pfizer, Inc.
2:15 pm - 2:30 pm	EGFRVIII Vaccine (CDX-110) Alone and with Simultaneous Temozolomide in Patients with Newly Diagnosed, Resected, EGFRVIII Positive GBM John Sampson, MD, PhD - Duke University Medical Center
2:30 pm - 3:00 pm	Novel Agents in Renal Cell Carcinoma: Challenges and Opportunities in Capitalizing on Active Therapy Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
3:20 pm - 4:45 pm	iSBTc Presidential Session Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
3:20 pm - 3:25 pm	Introduction Jon M. Wigginton, MD - Merck & Co., Inc.
3:25 pm - 3:45 pm	Apoptosis of Circulating Tumor-Antigen Specific TH1 CD4+ T Cells from Melanoma Patients Amy K. Wesa, PhD - University of Pittsburgh School of Medicine
3:45 pm - 4:05 pm	Priming and Selection of Allorestricted, Peptide-Specific T Cells for Adoptive Therapy of Tumors Susanne Wilde - Institute of Molecular Immunology
4:05 pm - 4:25 pm	Retrospective Analysis of Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma Who had Received Prior Antiangiogenic Therapy Talya Schwarzberg, MD - Beth Israel Deaconess Medical Center
4:25 pm - 4:45 pm	CD4+CD25highFoxp3+ T Regulatory Cells Kill Autologous CD8(+) and CD4(+) T Cells Using GranzymeB and Fas/FasL-Mediated Pathways Laura Strauss, PhD - San Raffaele Telethon Institute for Gene Therapy
Sunday, November 4
8:00 am - 8:30 am	Update: 2006 Mini-Symposium Update Chair: George Coukos, MD, PhD - University of Pennsylvania Medical Center Speaker: Michael B. Atkins, MD - Beth Israel Deaconess Medical Center
8:30 am - 8:45 am	Update: National Cancer Institute Immunotherapy Agent Workshop Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center
8:45 am - 11:00 am	Plenary Session: Vaccines / Dendritic Cells Co-Chair: Mary L. Disis, MD - University of Washington Lothar H. Finke, MD - ARGOS Therapeutics
8:45 am - 9:15 am	The Development of Provenge® (Sipuleucel-T) an Active Cellular Immunotherapy for Prostate Cancer David L. Urdal, PhD - Dendreon Corporation
9:15 am - 9:30 am	Long-Term Survival in Patients with Metastatic Melanoma Vaccinated with Melanoma-Antigen Loaded Dendritic Cells Joseph W. Fay, MD - Baylor University Medical Center
9:30 am - 9:45 am	Phase II Trial of a 10-Epitope CTL Vaccine, IDM-2101, in Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy Minal Barve, MD - Mary Crowley Cancer Research Centers
9:45 am - 10:00 am	Different DC Populations Interact with Memory & Effector T Cells, or with Treg Cells Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
10:00 am - 10:15 am	Features of Lympoid Neogenesis After Dermal Injection of Incomplete Freund’s Adjuvant with or without Peptides Craig L. Slingluff, Jr., MD - University of Virginia
10:15 am - 10:30 am	IMA901, a Novel Multi-Peptide Vaccine for the Treatment of Renal Cell Carcinoma - Pre-Clinical and Clinical Studies and Implications for Combination with Other Agents Harpreet Singh, PhD - Immatics Biotechnologies GmbH
10:30 am - 11:00 am	Insulin like Growth Factor Receptor Family Members: Essential Tumor Antigens in Breast Cancer Mary L. Disis, MD - University of Washington
11:00 am - 11:15 am	Refreshment Break
11:15 am - 12:45 pm	Hot Topic Sessions: Vaccines / Dendritic Cells Moderators: Bernard A. Fox, PhD - Earle A. Chiles Research Institute Jon M. Wigginton, MD - Merck & Co., Inc. Participants: Brent A. Blumenstein, PhD - TriArc Consulting Lee S. Simon, MD - Beth Israel Deaconess Medical Center Charles Drake, MD, PhD - Johns Hopkins University David L. Urdal, PhD - Dendreon Corporation James W. Young, MD - Memorial Sloan-Kettering Cancer Center
12:45 pm	Meeting Adjourns

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.